OTCMKTS:PDDPF - Medexus Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.38
  • Forecasted Upside: 160.09 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.22
▲ +2.975 (1,214.29%)

This chart shows the closing price for PDDPF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medexus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PDDPF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDDPF

Analyst Price Target is $8.38
▲ +160.09% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is $8.38, with a high forecast of $9.50 and a low forecast of $7.25. The average price target represents a 160.09% upside from the last price of $3.22.

This chart shows the closing price for PDDPF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Medexus Pharmaceuticals. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/17/2021Canaccord GenuityBoost Price TargetHold$5.25 ➝ $9.50
8/13/2020Stifel NicolausBoost Price TargetBuy$7.00 ➝ $7.25
3/27/2020Canaccord GenuityDowngradeBuy
(Data available from 7/23/2016 forward)

Medexus Pharmaceuticals

Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company. It provide healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company products include Rasuvo, Metoject and Rupall. Medexus was founded by Sylvain Chretien in January 2008 and is headquartered in Verdun, Canada.
Read More

Today's Range

Now: $3.22
Low: $3.16
High: $3.24

50 Day Range

MA: $3.16
Low: $0.25
High: $3.22

52 Week Range

Now: $3.22
Low: $1.70
High: $3.99

Volume

4,200 shs

Average Volume

4,355 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medexus Pharmaceuticals?

The following equities research analysts have issued reports on Medexus Pharmaceuticals in the last twelve months: Canaccord Genuity, and Stifel Nicolaus.
View the latest analyst ratings for PDDPF.

What is the current price target for Medexus Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Medexus Pharmaceuticals in the last year. Their average twelve-month price target is $8.38, suggesting a possible upside of 160.1%. Canaccord Genuity has the highest price target set, predicting PDDPF will reach $9.50 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $7.25 for Medexus Pharmaceuticals in the next year.
View the latest price targets for PDDPF.

What is the current consensus analyst rating for Medexus Pharmaceuticals?

Medexus Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PDDPF will outperform the market and that investors should add to their positions of Medexus Pharmaceuticals.
View the latest ratings for PDDPF.

What other companies compete with Medexus Pharmaceuticals?

How do I contact Medexus Pharmaceuticals' investor relations team?

The company's listed phone number is (514) 762-2626. The official website for Medexus Pharmaceuticals is www.medexus.com.